Lured by high demand, Korean wholesaler smuggled Novo’s obesity drug Saxenda into China

novo2
A Korean wholesaler is reportedly under investigation for allegedly smuggling Novo Nordisk's Saxenda to China. (Novo Nordisk)

Anti-obesity drug Saxenda has been one of Novo Nordisk’s key growth drivers lately—and apparently, a Korean wholesaler noticed. The pharmaceutical middleman allegedly smuggled the popular drug into China, where it’s not yet approved.

Korean regulators are investigating the wholesaler for allegedly hawking Saxenda in China, Korea Biomedical Review reported, citing multiple sources.

A Novo spokeswoman confirmed to FiercePharma that the company was made aware of the incident but declined to comment on the company’s launch plans for Saxenda in China.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

“We have been in dialogue with our distributor who has immediately terminated the contract with the wholesaler,” she said.

Novo Nordisk wasn’t aware of the situation before the probe emerged, according to the Korean media outlet. “Frankly speaking, we are dumbfounded,” a Novo official was quoted as saying. “This happened because it was difficult to control sub-distributors. We will do our best not to repeat the same mistake.”

While Saxenda is not available in China, its sister drug, diabetes blockbuster Victoza—which contains the same active ingredient, liraglutide—was approved in China in 2011 and was added to the country’s national reimbursement system last year.

RELATED: Novo Nordisk expands job cuts to 1,300 as executives play down Lilly’s GLP-1 threat

Saxenda was approved by the FDA in late 2014 and introduced in Korea last July. The obesity drug has been posting fast growth recently, alongside Novo’s overall GLP-1 franchise. For the first nine months of 2018, sales jumped 53% in local currencies to 2.64 billion Danish krone ($402 million); its business in Japan and Korea chipped in on that growth, said Novo in its third-quarter report. According to Korea Biomedical Review, huge demand often depleted supply in Korea, and the sentiment, if not the drug itself, has spread to its neighbor China.

The drug’s Korean distributor, Zuellig Pharma, is one of the largest healthcare services groups in Asia. It has distribution and logistics collaboration deals in the region with some of the biggest international biopharma companies, including Roche, GlaxoSmithKline, Pfizer, and Merck & Co., known as MSD in Asia. In 2010, its Chinese operation was scooped up by Cardinal Health, which wanted to expand its Chinese business, and it in turn was sold to Shanghai Pharma last November for $557 million.

RELATED: Market leader Novo Nordisk still has lots of upside in China's rapidly growing diabetes market: analyst

Drug smuggling has become a hot topic in China, thanks to a dark comedy movie, Dying to Survive, which was based on the true story of a leukemia patient who illegally sneaked in cheap Indian-made generics to Novartis’ Gleevec. But prescription drug smuggling in China is mainly associated with providing alternatives to high drug prices, rather than seeking personal gain on demand for an unapproved drug.

In China, all unapproved drugs are considered “counterfeit,” and those selling them could face sentences as high as three years in prison, and if casualties were involved, the penalty could go all the way up to a death sentence.

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.